Castle Biosciences Inc
NASDAQ:CSTL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Castle Biosciences Inc
Depreciation & Amortization
Castle Biosciences Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Castle Biosciences Inc
NASDAQ:CSTL
|
Depreciation & Amortization
$40.8m
|
CAGR 3-Years
57%
|
CAGR 5-Years
144%
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Depreciation & Amortization
$570m
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
6%
|
|
|
CVS Health Corp
NYSE:CVS
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cigna Corp
NYSE:CI
|
Depreciation & Amortization
$2.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
17%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Depreciation & Amortization
$681.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Depreciation & Amortization
$39.7m
|
CAGR 3-Years
3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Castle Biosciences Inc
Glance View
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.
See Also
What is Castle Biosciences Inc's Depreciation & Amortization?
Depreciation & Amortization
40.8m
USD
Based on the financial report for Dec 31, 2025, Castle Biosciences Inc's Depreciation & Amortization amounts to 40.8m USD.
What is Castle Biosciences Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
144%
Over the last year, the Depreciation & Amortization growth was 155%. The average annual Depreciation & Amortization growth rates for Castle Biosciences Inc have been 57% over the past three years , 144% over the past five years .
